SCHEMBL7126645

SCHEMBL7126645

O=[N+]([O-])c1ccccc1Oc1cccc(I)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 1/20 0.51
F10 P00742 1/20 0.50
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPT P10636 4/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
RECQL P46063 2/20 0.48
MAPK1 P28482 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 1/20 0.47
TBXA2R P21731 1/20 0.46
LTA4H P09960 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
HTT P42858 1/20 0.43
CETP P11597 1/20 0.43
ESR2 Q92731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10360452 0.89 L3MBTL1 (0.59) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL9688249 0.83 MAPT (0.58) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL7123876 0.82 L3MBTL1 (0.56) L3MBTL1HPGDALDH1A1TDP1MAPT
SCHEMBL238962 0.81 L3MBTL1 (0.62) L3MBTL1HPGDALDH1A1TDP1MAPT
SCHEMBL28219324 0.81 L3MBTL1 (0.62) L3MBTL1HPGDALDH1A1TDP1MAPT
SCHEMBL1340750 0.81 MAPT (0.57) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL1339905 0.81 L3MBTL1 (0.64) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL7997064 0.81 ALDH1A1 (0.55) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL31522154 0.81 ALDH1A1 (0.55) L3MBTL1HPGDF10ALDH1A1TDP1
SCHEMBL9131558 0.81 L3MBTL1 (0.51) L3MBTL1HPGDF10ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM L3MBTL1 2231/4885HPGD 919/4885F10 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.